To: shearson who wrote (16) | 4/17/2002 4:08:38 PM | From: tuck | | | I don't suppose you'd listen and take notes. I'm going on a road trip tomorrow, and will miss the earnings report from this and other similar companies that I try to follow. Might make it back before the replay expires, but I'll have a backlog of CCs to listen to by then and don't know if I'll get to them all.
FWIW, I have covered past calls on the Trickle thread.
TIA & Cheers, Tuck |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
To: tuck who wrote (17) | 7/23/2002 12:15:02 PM | From: shearson | | | Live Webcast of Epoch BioSciences, Inc. Q2 Earnings.
Epoch BioSciences, Inc. holds a live webcast of their Q2 Earnings conference call. This takes place on Tuesday, July 30, 2002 at 11:00 AM EST at the following link:
viavid.com
Join us for the Live Event at 11:00 AM EST. A replay will be available at the same link as above for 45 days from the conference date if you miss the live version.
Epoch Biosciences, Inc., formerly Epoch Pharmaceuticals, Inc., is developing and commercializing proprietary technologies to enhance the study of genes. Its scientists are applying their expertise in nucleic acid chemistry to develop products that improve methods of studying the genetic sequence (genomes) of humans, animals and plants.
ViaVid Broadcasting, Inc. provides teleconferencing and webcasting services to corporate clients throughout North America. These services utilize systems that integrate traditional telephony technology with powerful streaming media technology and Web-based tools. From a simple conference call to a dynamic online presentation, our clients are able to choose the communication solution that best meets their unique needs. ViaVid's communications expertise and in-house technology allows the company to provide these services on a very cost competitive basis.
ViaVid is a newly listed (fully reporting) company on the OTC-BB under the symbol: VVDB |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
To: tuck who wrote (17) | 9/18/2002 5:27:10 AM | From: mopgcw | | | Epoch Biosciences Insider Bought 94,505 Shares Thu-Fri
DOW JONES NEWSWIRES
WASHINGTON -- Epoch Biosciences Inc. (EBIO) insider Bradford T. Whitmore purchased 94,505 shares of the company's common stock Thursday and Friday, according to a Form 4 released Tuesday by the Securities and Exchange Commission.
Whitmore bought the shares for $1.12 and $1.15 a share. He directly owns 521,819 common shares and indirectly owns 5 million common shares.
Redmond, Wash.-based Epoch Biosciences develops and makes chemistry with commercial applications in the fields of genomics and molecular diagnostics.
Shares of the company recently traded at $1.14, down 5 cents or 4.6%. |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
From: shearson | 10/30/2002 4:19:16 PM | | | | Live Webcast of Epoch Biosciences, Inc. Q3 Earnings.
Epoch Biosciences holds a live webcast of their Q3 Earnings conference call. This takes place on Tuesday, November 5th, 2002 at 11:00 AM EST at the following link:
viavid.com
Join us for the live event at 11:00 am EST. A replay will be available at the same link as above for 45 days from the conference date if you miss the live version.
You can also join the conference call by dialing 1-888-277-8128 or 1-973-582-2729. To access the conference replay dial 1-877-519-4471 or 1-973-341-3080 and enter pin number 3558834. The replay will be available for one week following the call.
Epoch Biosciences, Inc., formerly Epoch Pharmaceuticals, Inc., is developing and commercializing proprietary technologies to enhance the study of genes. Its scientists are applying their expertise in nucleic acid chemistry to develop products that improve methods of studying the genetic sequence (genomes) of humans, animals and plants.
ViaVid Broadcasting, Inc. provides teleconferencing and webcasting services to corporate clients throughout North America. These services utilize systems that integrate traditional telephony technology with powerful streaming media technology and Web-based tools. From a simple conference call to a dynamic online presentation, our clients are able to choose the communication solution that best meets their unique needs. ViaVid's communications expertise and in-house technology allows the company to provide these services on a very cost competitive basis.
ViaVid is a newly listed (fully reporting) company on the OTC-BB under the symbol: VVDB |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: shearson who wrote (20) | 11/4/2002 6:38:23 PM | From: tuck | | | I will be listening to this CC. I believe this past and next two quarters are vital to EBIO. They said in a recent PR that R. A. Welch of NCI would be presenting at two conferences in October, regarding the use of Eclipse probes in RT PCR for SNP analysis. The conference in Iceland doesn't publish the abstracts. The ASHG does, but I could find only one abstract by an R. welch. He seems to be with the NCI and is involved with SNPs, but the abstract makes only the vaguest reference to the assays, certainly nothing about Eclipse probes.
Can't find any reference to them on the NCI SNP pages, either. None of this has stopped EBIO from making an impressive bounce from the under a buck area during these two conferences, and I missed my chance to pick some cheap EBIO up by waiting for it to go under $.80 again.
After tomorrow, I will decide how much I want to chase it.
Cheers, Tuck |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
To: tuck who wrote (22) | 12/11/2002 8:23:46 AM | From: dalroi | | | No new dillution :-)
Stefaan
Epoch Biosciences Applies to Transfer to Nasdaq SmallCap Market
BOTHELL, Wash., Dec. 11 /PRNewswire/ -- Epoch Biosciences, Inc. (NASDAQ:EBIO), a provider of proprietary products that accelerate genomic analysis, announced that it has applied to The Nasdaq Stock Market, Inc. to transfer the listing of its common stock from the Nasdaq National Market to the Nasdaq SmallCap Market. The company meets all the requirements of the Nasdaq National Market except for the new $10 million minimum stockholders' equity standard under Marketplace Rule 4450(a)(3). In its quarterly report on Form 10-Q for the period ended September 30, 2002, the Company reported stockholders' equity of approximately $8.7 million. The company expects to receive Nasdaq's approval decision within the next ten days and will maintain its current National Market status pending approval of the transfer application. The company believes that it meets all listing requirements of the Nasdaq SmallCap Market and anticipates approval of the transfer. The company's common stock will continue to be traded under the symbol "EBIO". William G. Gerber, chief executive officer, stated, "We believe the voluntary move to the Nasdaq SmallCap Market is in the best interest of our shareholders and is preferable to raising additional equity in order to meet the new stockholders equity standard. This move will allow us to continue to focus on the fundamentals of our business, which we believe is the best way to drive shareholder value |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
From: shearson | 2/24/2003 5:57:02 PM | | | | Live Conference Call & Webcast of Epoch BioSciences’ Q4 2002 Earnings.
Epoch BioSciences, Inc. holds a live webcast of their Q4 Earnings conference call. This takes place at 11:00 AM EST on Tuesday, February 25th, 2003 at the following link:
viavid.com
If you miss the live webcast, an archive will be available for 45 days at the same link as above.
To access the conference call dial 1-888-881-4892 or 1-416-640-4127. For the call replay dial 1-877-289-8525 or 1-416-640-1917 and enter passcode 238183#. The replay will be available for 1 week following the call.
Epoch Biosciences, Inc., formerly Epoch Pharmaceuticals, Inc., is developing and commercializing proprietary technologies to enhance the study of genes. Its scientists are applying their expertise in nucleic acid chemistry to develop products that improve methods of studying the genetic sequence (genomes) of humans, animals and plants.
ViaVid Broadcasting, Inc. provides teleconferencing and webcasting services to corporate clients throughout North America. These services utilize systems that integrate traditional telephony technology with powerful streaming media technology and Web-based tools. From a simple conference call to a dynamic online presentation, our clients are able to choose the communication solution that best meets their unique needs. ViaVid's communications expertise and in-house technology allows the company to provide these services on a very cost competitive basis. |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: shearson who wrote (24) | 9/17/2003 8:22:00 AM | From: dalroi | | | further on track
BOTHELL, Wash., Sept. 17 /PRNewswire-FirstCall/ -- Epoch Biosciences, Inc. (Nasdaq: EBIO), a provider of proprietary products that accelerate genomic analysis, announced it has entered into a worldwide non-exclusive license agreement with Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, for its Eclipse(TM) Dark Quencher technology.
As part of the license and supply agreement, Epoch Biosciences will supply Applied Biosystems its Eclipse Dark Quencher for incorporation into TaqMan(R) probes for use in 5' nuclease assays. The license covers use of the quencher technology for detection of microorganisms in the environment. The use of the Eclipse Dark Quencher on TaqMan probes expands the utility of Epoch's quencher technology into the field of environmental testing.
The license allows Applied Biosystems to manufacture, sell and distribute TaqMan(R) probes that carry Epoch's quencher. Under the license agreement, Epoch will receive license fees and royalties on Applied Biosystems' sales to purchasers of such licensed products.
William G. Gerber, M.D., chief executive officer of Epoch, said, "We have worked with Applied Biosystems for over four years and are pleased that they have chosen to expand this important business relationship. Applied Biosystems has extensive experience with Epoch technology and recognizes the value it brings to its TaqMan(R) products. This is the kind of value-added contribution we believe we can bring to partners and customers who place a premium on performance."
Eclipse Dark Quencher
The Eclipse Dark Quencher is a pioneering technology developed by Epoch Biosciences that when attached with a fluorescent dye to a DNA probe, suppresses the signal generated by the dye until the probe binds to its target DNA. It offers higher sensitivity in real-time PCR probes due to lower background fluorescence, is applicable in a broad range of detection systems, quenches of a broader dye emission spectra range, and is compatible with simple and robust DNA synthesis procedures.
The Eclipse Dark Quencher is currently incorporated into MGB Eclipse(TM) Probe Systems distributed for Epoch by Amersham Biosciences, in other TaqMan(R) products sold by Applied Biosystems, in the Invader System sold by Third Wave Technologies, and in QuantiTect gene expression assays sold by QIAGEN. The Eclipse Dark Quencher is also licensed to Takara for use in real-time PCR detection assays and is distributed by Glen Research for sale into the research community.
Previous Applied Biosystems and Epoch Technology Licensing Agreements
Epoch has previously licensed its MGB(TM) and Eclipse Dark Quencher technologies to Applied Biosystems for use in 5' nuclease real-time PCR assays. The original agreements and subsequent modifications are detailed in Epoch's Form 10-K and other filings |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
From: michael_f_murphy | 9/28/2003 2:27:27 AM | | | | Epoch Biosciences fails to win DOD contract Friday September 26, 6:15 pm ET
LOS ANGELES, Sept 26 (Reuters) - Epoch Biosciences Inc. (NasdaqSC:EBIO - News), a provider of products that accelerate genomic analysis, on Friday said it did not win a U.S. Department of Defense contract for a biological agent identification system. Epoch, based in Bothell, Washington, was a finalist in the competition for the program.
The company said it did not include revenue from the DOD project in its forecasts and its outlook for the fiscal year is unchanged.
Shares of Epoch fell 19 percent to close at $2.89 on Nasdaq |
| EBIO: Epoch Pharmaceuticals | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |